Targeting cellular senescence in dystrophin<sup>-/-</sup>/utrophin<sup>-/-</sup>double knockout mice improves musculoskeletal health and increases lifespan.

Pharmacol Res · 2025 · PMC12764366 · PMID 41173171

Europe PMC DOI

hedged sentence

0.0837

closest p · 1.7× alpha

0.0837

boldest claim

The sentences

showed a trendP = 0.0837so close (0.05 < p ≤ 0.1)

Ruxolitinib treatment showed a trend of increasing grip strength (P = 0.0837) compared to the control group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Targeting cellular senescence in dystrophin&lt;sup&gt;-/-&lt;/sup&gt;/utrophin&lt;sup&gt;-/-&lt;/sup&gt;double knockout mice improves musculoskeletal health and increases lifespan.

The sentences

Targeting cellular senescence in dystrophin<sup>-/-</sup>/utrophin<sup>-/-</sup>double knockout mice improves musculoskeletal health and increases lifespan.